Ma. Nader et M. Hannemann, INTERACTIONS OF BUSPIRONE OR GEPIRONE WITH NICOTINE ON SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS, Behavioural pharmacology, 4(3), 1993, pp. 263-268
The primary purpose of the present study was to examine the interactio
n of buspirone with nicotine in pigeons responding under a fixed-ratio
30 schedule of food presentation. The hypothesis was that the dopamin
e D2 receptor antagonist activity of buspirone would attenuate the rat
e-decreasing effects of nicotine. When administered alone, buspirone (
0.3-10 mg/kg) and (-) -nicotine (0.1-3.0 mg/kg) decreased response rat
es in a dose-related manner, with ED50 values (+/- 95% C.L.) of 3.0 (1
.7-5.1) mg/kg and 1.0 (0.7-1.5) mg/kg, respectively. Low doses of busp
irone (0.3-1.0 mg/kg) did not significantly shift the nicotine dose-re
sponse function, while doses of buspirone (3.0-10 mg/kg) that produced
rate-decreasing effects shifted the nicotine dose-response function t
o the left. There was no significant statistical interaction between b
uspirone and nicotine indicating that the shifts in the nicotine dose-
response function were parallel. The buspirone analog gepirone (0.3-10
mg/kg), which like buspirone is a serotonin (5-HT1A) agonist, but unl
ike buspirone is relatively devoid of D2 antagonist activity, was also
tested in combination with nicotine. Gepirone was less potent in decr
easing response rates compared with buspirone, with an ED50 value of 4
.5 (3.1-6.7) mg/kg. Rate-decreasing doses of gepirone (3.0-10 mg/kg) i
n combination with nicotine resulted in parallel shifts to the left of
the nicotine dose-response function. There was no statistically signi
ficant difference between the effects of buspirone and those of gepiro
ne on the nicotine dose-response function. Isobolograms indicated that
the pharmacological interactions between buspirone or gepirone and ni
cotine were not different from additivity. These results suggest that
the combined effects of buspirone and nicotine on schedule-controlled
behavior are independent of antagonism at D2 receptors.